Mitomicin Accord (Mitomycin)

Mitomycin, the active ingredient in Mitomicin Accord, is an alkylating agent presented as an injectable solution for intravenous and intravesical use. It is employed in the treatment of several solid tumours, including bladder, gastric, breast, and head‑and‑neck cancers, and is administered under the supervision of oncology specialists.

GNH USA supplies Mitomicin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global clinical demand.

Mitomicin Accord, an alkylating antineoplastic agent, is used in the management of solid tumours across several organ sites. - Bladder cancer (intravesical use): reduces tumour recurrence and progression after transurethral resection. - Gastric cancer: used as part of combination chemotherapy regimens to improve response rates. - Breast cancer: incorporated into multi‑drug protocols for advanced or metastatic disease. - Head and neck cancer: administered in concurrent chemoradiotherapy to enhance local control.

Mitomicin Accord may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset occurring in many patients. - Myelosuppression: reduced white blood cells, platelets, and red cells. - Fatigue: generalized tiredness during treatment. - Diarrhea: loose stools that may require supportive care.

Serious or Rare Side Effects: - Hemorrhagic cystitis: bladder inflammation with bleeding. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Severe neutropenia: markedly low neutrophil count increasing infection risk.

Prior to and during therapy, careful monitoring and supportive measures are recommended. - Monitor blood counts: perform regular CBC to detect myelosuppression. - Assess renal function: evaluate serum creatinine before and during therapy. - Hydration: ensure adequate fluid intake to reduce risk of bladder toxicity. - Avoid concurrent nephrotoxic drugs: limit exposure to agents that may impair kidney function. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Mitomicin Accord can interact with other medicines, influencing safety or effectiveness.

Major Interactions (Avoid): - Concurrent use with other alkylating agents: may increase cumulative bone marrow toxicity. - Combination with nephrotoxic antibiotics (e.g., aminoglycosides): heightens risk of renal damage.

Moderate Interactions (Monitor Closely): - Antifolate drugs (e.g., methotrexate): may enhance myelosuppression. - CYP450 inducers: could reduce plasma concentration of mitomycin. - Anticoagulants: increased bleeding risk due to potential mucosal damage.